Page 42 - IMO-2-3

Innovative Medicines & Omics Tyrosine kinases: Structure, mechanism, and therapeutics

doi: 10.1098/rsob.210218 structural biology to cytokine engineering. Signal Transduct
Target Ther. 2024;9(1):221.
40. Huang H. Anaplastic lymphoma kinase (ALK) receptor
tyrosine kinase: A catalytic receptor with many faces. Int J doi: 10.1038/s41392-024-01934-w
Mol Sci. 2018;19(11):3448.
52. Hellwig S, Miduturu CV, Kanda S, et al. Small-molecule
doi: 10.3390/ijms19113448 inhibitors of the c-Fes protein-tyrosine kinase. Chem Biol.
41. Hallberg B, Palmer RH. The role of the ALK receptor in 2012;19(4):529-540.
cancer biology. Ann Oncol. 2016;27:iii4-iii15. doi: 10.1016/j.chembiol.2012.01.020
doi: 10.1093/annonc/mdw301 53. Ivanova IA, Arulanantham S, Barr K, et al. Targeting FER
42. Siveen KS, Prabhu KS, Achkar IW, et al. Role of non receptor kinase inhibits melanoma growth and metastasis. Cancers
tyrosine kinases in hematological malignances and its (Basel). 2019;11(3):419.
targeting by natural products. Mol Cancer. 2018;17(1):31. doi: 10.3390/cancers11030419
doi: 10.1186/s12943-018-0788-y 54. Menegon A, Burgaya F, Baudot P, Dunlap DD, Girault JA,
43. Hubbard SR, Miller WT. Receptor tyrosine kinases: Valtorta F. FAK+ and PYK2/CAKbeta, two related tyrosine
Mechanisms of activation and signaling. Curr Opin Cell Biol. kinases highly expressed in the central nervous system:
2007;19(2):117-123. Similarities and differences in the expression pattern. Eur J
Neurosci. 1999;11(11):3777-3788.
doi: 10.1016/j.ceb.2007.02.010
doi: 10.1046/j.1460-9568.1999.00798.x
44. Kan Y, Paung Y, Seeliger MA, Miller WT. Domain
architecture of the nonreceptor tyrosine kinase Ack1. Cells. 55. Rigiracciolo DC, Cirillo F, Talia M, et al. Focal adhesion
2023;12(6):900. kinase fine tunes multifaced signals toward breast cancer
progression. Cancers (Basel). 2021;13(4):645.
doi: 10.3390/cells12060900
doi: 10.3390/cancers13040645
45. Prieto-Echagüe V, Gucwa A, Craddock BP, Brown DA,
Miller WT. Cancer-associated mutations activate the nonreceptor 56. Yin Z, Zou Y, Wang D, et al. Regulation of the Tec family of
tyrosine kinase Ack1. J Biol Chem. 2010;285(14):10605-10615. non-receptor tyrosine kinases in cardiovascular disease. Cell
Death Discov. 2022;8(1):119.
doi: 10.1074/jbc.M109.060459
doi: 10.1038/s41420-022-00927-4
46. Mahajan K, Mahajan NP. ACK1/TNK2 tyrosine kinase:
Molecular signaling and evolving role in cancers. Oncogene. 57. Hussain A, Yu L, Faryal R, Mohammad DK, Mohamed AJ,
2015;34(32):4162-4167. Smith CI. TEC family kinases in health and disease--loss-of-
doi: 10.1038/onc.2014.350 function of BTK and ITK and the gain-of-function fusions
ITK-SYK and BTK-SYK. FEBS J. 2011;278(12):2001-2010.
47. Ahmed S, Miller WT. The noncatalytic regions of the
tyrosine kinase Tnk1 are important for activity and substrate doi: 10.1111/j.1742-4658.2011.08134.x
specificity. J Biol Chem. 2022;298(12):102664. 58. Ortiz MA, Mikhailova T, Li X, Porter BA, Bah A, Kotula L.
doi: 10.1016/j.jbc.2022.102664 Src family kinases, adaptor proteins and the actin
cytoskeleton in epithelial-to-mesenchymal transition. Cell
48. Sawant M, Wilson A, Sridaran D, et al. Epigenetic Commun Signal. 2021;19(1):67.
reprogramming of cell cycle genes by ACK1 promotes
breast cancer resistance to CDK4/6 inhibitor. Oncogene. doi: 10.1186/s12964-021-00750-x
2023;42(29):2263-2277. 59. Kovács M, Németh T, Jakus Z, et al. The Src family kinases
doi: 10.1038/s41388-023-02747-x Hck, Fgr, and Lyn are critical for the generation of the
in vivo inflammatory environment without a direct role in
49. Lupardus PJ, Ultsch M, Wallweber H, Bir Kohli P, leukocyte recruitment. J Exp Med. 2014;211(10):1993-2011.
Johnson AR, Eigenbrot C. Structure of the pseudokinase-
kinase domains from protein kinase TYK2 reveals a doi: 10.1084/jem.20132496
mechanism for Janus kinase (JAK) autoinhibition. Proc Natl 60. Pelaz SG, Tabernero A. Src: Coordinating metabolism in
Acad Sci U S A. 2014;111(22):8025-8030. cancer. Oncogene. 2022;41(45):4917-4928.
doi: 10.1073/pnas.1401180111 doi: 10.1038/s41388-022-02487-4
50. Caveney NA, Saxton RA, Waghray D, et al. Structural basis of 61. Goel RK, Kim N, Lukong KE. Seeking a better understanding
Janus kinase trans-activation. Cell Rep. 2023;42(3):112201. of the non-receptor tyrosine kinase, SRMS. Heliyon.
doi: 10.1016/j.celrep.2023.112201 2023;9(6):e16421.
51. Lv Y, Qi J, Babon JJ, et al. The JAK-STAT pathway: From doi: 10.1016/j.heliyon.2023.e16421

Volume 2 Issue 3 (2025) 36 doi: 10.36922/IMO025200022